Renascience Inc.

As of March 31, 2026, Renascience Inc. carries a market capitalization of 23.12B, placing it among publicly traded companies globally. Its enterprise value stands at 19.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Renascience Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of March 31, 2026, Renascience Inc. has 13.78M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Renascience Inc. maintains a current ratio of 19.40, meaning it holds 19.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Renascience Inc.'s stock has declined approximately 49.77% over the past 52 weeks. The 50-day moving average sits at 1,178.42, while the 200-day moving average is 1,477.97.

These figures are as of March 31, 2026. Total book value stands at 3.32B, with working capital of 3.32B providing operational flexibility.